CEO Serlin Keeps Shares Flat as BioLine RX Faces GLIX1 Trial Uncertainty — Signal of Long‑Term Confidence Amid Market Volatility
CEO Serlin Philip A keeps BioLine RX shares steady amid volatility, reflecting confidence in GLIX1 trials and a structured option plan that could boost share value.
3 minutes to read